Research programme: VEGF-B protein therapy - Zenyth Therapeutics
Alternative Names: AM-133Latest Information Update: 19 Apr 2010
At a glance
- Originator Zenyth Therapeutics
- Class Proteins
- Mechanism of Action Angiogenesis inducing agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 01 Dec 2005 Amrad Corporation is now called Zenyth Therapeutics
- 06 May 2005 This compound is still in active development
- 06 May 2005 AM 133 is available for licensing (http://www.amrad.com)